Sympathetic ophthalmia usually occurs following a perforating injury to one eye. The mechanism of inducing the inflammatory process in the second eye is not clearly understood, but it is felt by many that "autosensitization" to uveal tissue plays an important role in the evolution of the disease process.1-16 Prior to the advent of corticosteroid therapy,17-20 this condition generally followed a chronic progressive course which resulted in irreparable damage to the eyes.
Within the past decade, a number of inflammatory conditions, presumed to have an underlying autoimmune mechanism, have been reported to respond favorably to certain antitumor agents.21 These antimetabolites are known to possess immunosuppressive and anti-inflammatory properties. One of these agents, methotrexate, has recently been shown to be effective in the therapy of several patients with steroid-resistant cyclitis.22
It is the purpose of this communication to report the successful treatment of a case of sympathetic ophthalmia
WONG VG, HERSH EM, McMASTER PRB. Treatment of a Presumed Case of Sympathetic Ophthalmia With Methotrexate. Arch Ophthalmol. 1966;76(1):66–76. doi:10.1001/archopht.1966.03850010068014
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: